Design Therapeutics, Inc. $DSGN Shares Bought by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP raised its holdings in Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) by 45.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 431,840 shares of the company's stock after purchasing an additional 133,919 shares during the quarter. Dimensional Fund Advisors LP owned 0.69% of Design Therapeutics worth $4,593,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. AlphaCentric Advisors LLC lifted its holdings in shares of Design Therapeutics by 4.8% in the 1st quarter. AlphaCentric Advisors LLC now owns 21,231 shares of the company's stock valued at $226,000 after buying an additional 969 shares during the period. Bank of America Corp DE grew its holdings in Design Therapeutics by 11.1% during the second quarter. Bank of America Corp DE now owns 24,625 shares of the company's stock worth $83,000 after acquiring an additional 2,459 shares during the period. Strs Ohio raised its position in Design Therapeutics by 11.5% during the fourth quarter. Strs Ohio now owns 25,200 shares of the company's stock valued at $236,000 after acquiring an additional 2,600 shares in the last quarter. Russell Investments Group Ltd. raised its position in Design Therapeutics by 69.6% during the third quarter. Russell Investments Group Ltd. now owns 6,377 shares of the company's stock valued at $48,000 after acquiring an additional 2,618 shares in the last quarter. Finally, Torren Management LLC acquired a new position in Design Therapeutics in the fourth quarter valued at approximately $26,000. 56.64% of the stock is owned by institutional investors and hedge funds.

Design Therapeutics Stock Performance

Design Therapeutics stock opened at $14.62 on Wednesday. The stock has a market capitalization of $914.92 million, a P/E ratio of -12.39 and a beta of 1.63. The company's fifty day moving average price is $12.88 and its 200 day moving average price is $11.91. Design Therapeutics, Inc. has a 1 year low of $4.68 and a 1 year high of $17.25.

Design Therapeutics (NASDAQ:DSGN - Get Free Report) last posted its quarterly earnings data on Monday, August 3rd. The company reported ($0.32) earnings per share for the quarter, topping analysts' consensus estimates of ($0.34) by $0.02. Sell-side analysts predict that Design Therapeutics, Inc. will post -1.41 EPS for the current year.

Analyst Ratings Changes

Several research firms have commented on DSGN. Oppenheimer upped their price objective on Design Therapeutics from $18.00 to $21.00 and gave the stock an "outperform" rating in a research report on Monday, May 4th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Design Therapeutics in a report on Friday, July 17th. Piper Sandler reiterated an "overweight" rating and issued a $20.00 target price on shares of Design Therapeutics in a research note on Wednesday, April 29th. Wall Street Zen upgraded shares of Design Therapeutics from a "sell" rating to a "hold" rating in a research note on Sunday, May 10th. Finally, Cantor Fitzgerald initiated coverage on shares of Design Therapeutics in a report on Tuesday, May 12th. They set an "overweight" rating on the stock. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $16.50.

Design Therapeutics Company Profile

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders.

Want to see what other hedge funds are holding DSGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source